Abstract
HLA class I antigens play a key role in immune recognition of transformed and virally infected cells via binding to the peptides of “non-self” or aberrantly expressed proteins and subsequent presentation of the newly formed “HLA-I-peptide” complex to T lymphocytes. Consequently, a chain of immune reactions is initiated leading to tumor cell elimination by cytotoxic T cells. Altered tumor expression of HLA class I is frequently observed in various types of malignancies. It represents one of the main mechanisms used by cancer cells to evade immunosurveillance. Because of immune selection, HLA class I-negative variants escape and lead to tumor growth and metastatic colonization. Loss or downregulation of HLA class I antigens on tumor cell surface is a factor that limits clinical outcome of peptide-based cancer vaccines aimed to increasing specific anti-tumor activity of cytotoxic T lymphocytes. Thus, gaining more knowledge regarding frequency of HLA class I defect, its tissue specificity, and underlying molecular mechanisms may help designing appropriate therapeutic strategies in cancer treatment. Here, we describe various types of HLA class I alterations found in different malignancies and molecular mechanisms that underlie these defects. We also discuss a correlation between HLA class I defects cancer progression in melanoma patients with poor clinical response to autologous vaccination.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Aptsiauri, N., Cabrera, T., Garcia-Lora, A., Lopez-Nevot, M.A., Ruiz-Cabello, F. and Garrido, F. (2007) MHC class I antigens and immune surveillance in transformed cells. Int. Rev. Cytol. 256, 139–189.
Cabrera, T., Lopez-Nevot, M.A., Gaforio, J.J., Ruiz-Cabello, F. and Garrido, F. (2003) Analysis of HLA expression in human tumor tissues. Cancer Immunol. Immunother. 52, 1–9.
Cabrera, T., Lara E., Romero, J.M., Maleno, I., Real, L.M., Ruiz-Cabello, F., Valero, P., Camacho, F.M. and Garrido, F. (2007) HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination. Cancer Immunol. Immunother. 56, 709–717.
Garcia-Lora, A., Algarra, I. and Garrido, F. (2003) MHC class I antigens, immune surveillance, and tumor escape. J. Cell. Physiol. 195, 346–55.
Garrido, F., Festenstein, H. and Schirrmacher, V. (1976) Further evidence for depression of H-2 and Ia-like specificities of foreign haplotypes in mouse tumour cell lines. Nature 261, 705–707.
Garrido, F., Cabrera, T., Concha, A., Glew, S., Ruiz-Cabello, F. and Stern, P.L. (1993) Natural history of HLA expression during tumour development. Immunol. Today 14, 491–499.
Garrido, F., Cabrera, T., Lopez-Nevot, M.A. and Ruiz-Cabello, F. (1995) HLA class I antigens in human tumors. Adv. Cancer Res. 67, 155–195.
Garrido, F., Ruiz-Cabello, F., Cabrera, T., Perez-Villar, J.J., Lopez-Botet, M., Duggan-Keen, M. and Stern, P.L. (1997) Implications for immunosurveilance of altered HLA class I phenotypes in human. Immunol. Today 18, 89–95.
Garrido, F. and Algarra, I. (2001) MHC antigens and tumor escape from immune surveillance. Adv. Cancer Res. 83, 117–158.
Kageshita, T., Ishihara, T., Campoli, M. and Ferrone, S. (2005) Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions. Tissue Antigens 65, 419–428.
Khong, H.T. and Restifo, N.P. (2002) Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat. Immunol. 3, 999–1005.
Koene, G.J., Arts-Hilkes, Y.H., van der Ven, K.J., Rozemuller, E.H., Slootweg, P.J., de Weger, R.A. and Tilanus, M.G. (2004) High level of chromosome 15 aneuploidy in head and neck squamous cell carcinoma lesions identified by FISH analysis: limited value of beta2-microglobulin LOH analysis. Tissue Antigens 64, 452–461.
Koopman, L.A., Mulder, A., Corver, W.E., Anholts, J.D., Giphart, M.J., Claas, F.H. and Fleuren, G.J. (1998) HLA class I phenotype and genotype alterations in cervical carcinomas and derivative cell lines. Tissue Antigens 51, 623–636.
Koopman, L.A., Corver, W.E., van der Slik, A.R., Giphart, M.J. and Fleuren, G.J. (2000) Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J. Exp. Med. 191, 961–976.
Maleno, I., Lopez-Nevot, M.A., Cabrera, T., Salinero, J. and Garrido, F. (2002) Multiple mechanisms generate HLA altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Cancer Immunol. Immunother. 51, 389–396.
Paschen, A., Mendez, R.M., Jimenez, P., Sucker, A., Ruiz-Cabello, F., Song, M., Garrido, F. and Schadendorf, D. (2003) Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events. Int. J. Cancer 103, 759–767.
Paschen, A., Arens, N., Sucker, A., Greulich-Bode, K.M., Fonsatti, E., Gloghini, A., Striegel, S, Schwinn, N., Carbone, A., Hildenbrand, R., Cerwenka, A., Maio, M. and Schadendorf, D. (2006) The coincidence of chromosome 15 aberrations and beta2-microglobulin gene mutations is causative for the total loss of human leukocyte antigen class I expression in melanoma. Clin. Cancer Res. 12, 3297–3305.
Pawelec, G. and Marsh, S.G. (2006) ESTDAB: a collection of immunologically characterised melanoma cell lines and searchable databank. Cancer Immunol. Immunother. 55, 623–627.
Ramal, L.M., Feenstra, M., van der Zwan, A.W., Collado, A., Lopez-Nevot, M.A., Tilanus, M. and Garrido, F. (2000) Criteria to define HLA haplotype loss in human solid tumors. Tissue Antigens 55, 443–448.
Romero, J.M., Jimenez, P., Cabrera, T., Pedrinaci, S., Tallada, M., Garrido, F. and Ruiz-Cabello, F. (2005) Coordinated downregulation of the antigen presentation machinery and HLA class I/beta2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer. Int. J. Cancer 113, 605–610.
Rosenberg, S.A., Yang, J.C. and Restifo, N.P. (2004) Cancer immunotherapy: moving beyond current vaccines. Nature Med. 10, 909–915.
Seliger, B., Cabrera, T., Garrido, F. and Ferrone, F. (2002) HLA class I antigen abnormalities and immune escape by malignant cells. Semin. Cancer Biol. 12, 3–13.
Shurin, M.R., Shruin, G., Lokshin, A., Yurkovetsky, Z.R., Gutkin, D.W., Chatta, G., Zhong, H., Han, B. and Ferris, R.L. (2006) Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies? Cancer Met. Rev. 25, 333–356.
Smyth, M.J., Dunn, G.P. and Schreiber, R.D. (2006) Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv. Immunol. 90, 1–50.
Watson, N.F., Ramage, J.M., Madjd, Z., Splendlove, I., Ellis, I.O., Scholefeld, J.H. and Schreiber, R.D. Durrant, L.G. (2006) Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int. J. Cancer 118, 6–10.
Zitvogel, L., Tesniere, A. and Schreiber, R.D. Kroemer, G. (2006) Cancer despite immunosurveillance: immunoselection and immunosubversion. Nature Rev. Immunol. 6, 715–727.
Zou, W. (2005) Immunosupressive networks in the tumor environment and their therapeutic relevance. Nature Rev. Cancer 5, 263–274.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer Science+Business Media, LLC
About this paper
Cite this paper
Aptsiauri, N., Cabrera, T., Mendez, R., Garcia-Lor, A., Ruiz-Cabello, F., Garrido, F. (2007). Role of Altered Expression of HLA Class I Molecules in Cancer Progression. In: Shurin, M.R., Smolkin, Y.S. (eds) Immune-Mediated Diseases. Advances in Experimental Medicine and Biology, vol 601. Springer, New York, NY. https://doi.org/10.1007/978-0-387-72005-0_13
Download citation
DOI: https://doi.org/10.1007/978-0-387-72005-0_13
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-72004-3
Online ISBN: 978-0-387-72005-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)